Scarica l'app Stockscreener
38.27
2.03%
0.76
Dopo l'orario di chiusura:
38.27
Precedente Chiudi:
$37.51
Aprire:
$38.04
Volume 24 ore:
791.18K
Relative Volume:
0.93
Capitalizzazione di mercato:
$2.23B
Reddito:
$899.11M
Utile/perdita netta:
$145.62M
Rapporto P/E:
15.41
EPS:
2.4829
Flusso di cassa netto:
$322.54M
1 W Prestazione:
-3.36%
1M Prestazione:
-9.25%
6M Prestazione:
+30.97%
1 anno Prestazione:
+43.71%
Intervallo 1D:
$38.00
$39.00
Intervallo di 1 settimana:
$35.99
$40.57
Portata 52W:
$25.52
$43.49
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
38.27 | 2.23B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-26 | Iniziato | Wolfe Research | Outperform |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Downgrade | Truist | Buy → Hold |
| 2026-02-11 | Ripresa | UBS | Neutral |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
Why Harmony Biosciences Stock Got Mashed on Monday - The Motley Fool
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth - Investing News Network
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth - GlobeNewswire Inc.
HRMY vs. CSLLY: Which Stock Is the Better Value Option? - Zacks Investment Research
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Zacks Investment Research
Harmony Biosciences Holdings (NasdaqGM:HRMY) Stock Forecast & Analyst Predictions - Simply Wall Street
Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harmony Biosciences CMO sells $1.65m in shares By Investing.com - Investing.com South Africa
Harmony Biosciences CMO sells $1.65m in shares By Investing.com - Investing.com Australia
Harmony Biosciences CMO sells $1.65m in shares - Investing.com
Harmony Biosciences (HRMY) CMO exercises options and sells shares - Stock Titan
$1.5M stock sale planned by Harmony Biosciences (NASDAQ: HRMY) officer - Stock Titan
Harmony Biosciences Holdings Insider Sold Shares Worth $1,655,416, According to a Recent SEC Filing - Yahoo Finance
After preset plan trades, Harmony Biosciences (NASDAQ: HRMY) officer plans 800-share sale - Stock Titan
Harmony Biosciences Holdings, Inc.Common Stock (Nasdaq:HRMY) Price Chart - The Chronicle-Journal
Officer stock sale at Harmony Biosciences (NASDAQ: HRMY) follows earlier 10b5-1 trades - Stock Titan
(HRMY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HRMY: Pipeline expansion, BP-205 progress, and BD deals drive next phase of growth - TradingView
Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs - Benzinga
Harmony Biosciences CMO Kumar Budur Executes Stock Sales and Option Exercises in Early September 2026 - Kalkine Media
Harmony Biosciences (NASDAQ: HRMY) CMO exercises 22,954 options, sells shares under trading plan - Stock Titan
Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing - Yahoo Finance
Harmony Biosciences (NASDAQ: HRMY) officer lines up a seven-figure stock sale - Stock Titan
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - Eastern Progress
Harmony Biosciences stock holds near USD 41.86 - AD HOC NEWS
Harmony Biosciences (HRMY) executive to sell about $230K in stock - Stock Titan
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report? - Yahoo Finance
Harmony Biosciences to Present Encore EPX-100 Data from ARGUS Study at 16th European Epilepsy Congress - Quiver Quantitative
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress - Yahoo Finance
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com South Africa
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com Canada
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com India
Harmony Biosciences stock hits 52-week high at $42.70 - Investing.com
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones - Stock Traders Daily
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - Investing News Network
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - GlobeNewswire
HRMY Initiates Coverage On Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates Harmony Biosciences stock at Outperform - Investing.com
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com Canada
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com UK
Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Stephen M. Mollichella Net Worth (2026) - GuruFocus
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Harmony Biosciences Holdings Inc Azioni (HRMY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KUMAR BUDUR | Officer |
Sep 18 '26 |
Proposed Sale |
42.74 |
35,852 |
1,532,314 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 18 '26 |
Sale |
43.05 |
35,852 |
1,543,590 |
13,115 |
| KUMAR BUDUR | Officer |
Sep 17 '26 |
Proposed Sale |
42.21 |
800 |
33,768 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Option Exercise |
30.48 |
800 |
24,384 |
13,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Sale |
43.00 |
800 |
34,400 |
13,115 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Option Exercise |
30.48 |
1,800 |
54,864 |
14,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Sale |
43.01 |
1,800 |
77,426 |
13,115 |
| KUMAR BUDUR | Officer |
Sep 16 '26 |
Proposed Sale |
42.17 |
1,800 |
75,906 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 08 '26 |
Option Exercise |
30.49 |
22,954 |
699,942 |
36,069 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 08 '26 |
Sale |
42.96 |
28,454 |
1,222,258 |
13,115 |
0.72%
4.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):